cGMP Audit and API Specification Report: Blue Eyes Biotech L-Lysine Confirmed as a Reliable Drug Substance for Pharmaceutical Applications

Article Title: cGMP Audit and API Specification Report: Blue Eyes Biotech L-Lysine Confirmed as a Reliable Drug Substance for Pharmaceutical Applications

Page Description: This audit report covers both the analytical quality and the manufacturing compliance of Blue Eyes Biotech L-Lysine as a potential Active Pharmaceutical Ingredient (API). The review confirms adherence to ICH Q7 guidelines, a comprehensive impurity profile, and suitability for parenteral and oral dosage forms.

Body:

Intended for pharmaceutical quality assurance units, regulatory affairs specialists, and API procurement managers, this dual-focus report

combines a rigorous analytical specification review with an assessment of manufacturing controls for L-Lysine produced by Blue Eyes

Biotech CO., Ltd. Selecting an API supplier requires confidence in both the product and the production system.

The analytical section goes beyond standard monographs. A full impurity profile was established using advanced chromatographic

techniques. Known and unknown impurities were quantified and found to be consistently below the Identification Threshold as per ICH Q3A

guidelines. Specific tests for residual solvents (Class 1, 2, and 3) confirmed compliance with ICH Q3C recommendations. Furthermore,

endotoxin testing (LAL method) was performed, with results proving the material is suitable for consideration in the formulation of parenteral (injectable) nutrition solutions, a critical application for hospital-grade products.

Concurrently, a documentary audit of the manufacturing facility's quality system was conducted against the principles of ICH Q7 for Active Pharmaceutical Ingredients. The audit found that Blue Eyes Biotech employs a validated manufacturing process for its L-Lysine, with established critical process parameters (CPPs) and in-process controls (IPCs). The facility maintains comprehensive documentation, including batch manufacturing records, change control procedures, and a robust stability program. The audit trail from raw material receipt to finished API release was found to be complete and traceable.

The synthesis of analytical and compliance data presents a compelling case. Blue Eyes Biotech L-Lysine is not merely a high-purity chemical; it is an API produced under a cGMP-aligned quality management system. This makes it a viable and reliable source for pharmaceutical companies developing oral solid dosages, effervescent tablets, or critical sterile solutions where ingredient pedigree and documented control are non-negotiable.

To request the Pharmaceutical Development Dossier, impurity profile reports, or to initiate a supplier qualification audit, please contact.

Company:Blue Eyes Biotech CO., Ltd

Email:[email protected]

Website:www.blueeyes-bio.com

WhatsApp:+66840769830

Keywords: L-Lysine API, Pharmaceutical drug substance, cGMP manufacturing, ICH Q7 guidelines, Impurity profile, Endotoxin testing, Parenteral nutrition, Pharmaceutical audit, Blue Eyes Biotech

Facebook Tags:

#API#PharmaceuticalManufacturing #cGMP #ICHGuidelines #DrugSubstance #Parenteral #PharmaQuality #BlueEyesBiotech #APISupplier